Review Article
Year: 2020 | Month: February | Volume: 7 | Issue: 2 | Pages: 434-447
Pharmacotherapy of Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
Anil Saleem K
Senior Consultant Cardiologist, Aster MIMS hospital, Mini Bypass Road Govindapuram, Kozhikode, Kerala, 673016
ABSTRACT
Heart failure (HF) is a common clinical syndrome and a global health priority. It is a multifactorial, progressive and debilitating condition and requiring lifelong management. Despite the advances in drug therapy and management strategies, which is usually presents as a disease syndrome, has been a challenge to healthcare providers. This is demonstrated by high rates of hospital readmissions along with increased mortality and morbidity associated with heart failure. In this review article, we focused on pharmacotherapy of heart failure and we determined management guidelines and recent advances in the management of chronic heart failure with reduced ejection fraction (HFrEF). The standard therapy along with lifestyle modifications plays an important role in determining the prognosis of the disease. Recent advances in drug therapies and consequent use of established medication have substantially minimizes the readmissions and improves quality of life in heart failure patients with reduced ejection fraction. We consider that this article provide an extensive overview of heart failure in terms of stages, disease pathophysiology, pharmacotherapy and recent advances in the management of chronic heart failure with reduced ejection fraction.
Keywords: Heart failure, ejection fraction, pharmacotherapy, management guidelines and recent advances.
[PDF Full Text]